Now I have all the information I need. Let me write the final consolidated review.

## Summary

ProteinVista introduces a full-atom 3D CNN that voxelizes heavy atoms at 1.0 Å resolution, uses adaptive boxing to handle proteins of varying sizes, and is pretrained on ~500K AlphaFold2 structures via contrastive alignment to ESM-2 embeddings. The model is evaluated on enzyme-substrate classification, transporter-substrate classification, and drug-target IC50 regression, consistently matching or outperforming ESM-2 (including the 650M-parameter variant) while using 5× fewer parameters and orders of magnitude less pretraining data. An ensemble with ESM-2 yields further gains on classification tasks, demonstrating complementary sequence-structure signals. The paper also reports compute efficiency advantages and an honest assessment of limitations (e.g., weaker performance on homology-driven GO prediction, storage costs for 3D coordinates).

## Strengths

- **Clear outperformance of ESM-2 on structure-sensitive tasks.** Table 2 shows ProteinVista achieves R² = 0.69 on BindingDB IC50 regression vs. 0.61 for ESM-2₆₅₀M, while using 123M vs. 650M parameters and ~500K vs. 250M pretraining examples. Table 1 shows ProteinVista matching or exceeding ESM-2 on two substrate classification benchmarks.

- **Compute efficiency is convincingly demonstrated.** Section 4.3 reports ProteinVista processes 1,000 proteins in ~20s on an A100 vs. 426s for ESM-2₆₅₀M. Pretraining required 48 hours on 4 A100s vs. ~7 days on 128 H100s for ESM-2₆₅₀M. The FLOPs comparison (415 vs. 520 GFLOPs per input) and the explanation that 3D CNNs parallelize better than deep transformer stacks are well-supported.

- **Ensemble with ESM-2 yields statistically significant complementary gains** (p < 10⁻¹³ on TSP, p < 10⁻¹⁷ on ESP), and the stratified analysis by sequence identity, structural similarity, and pLDDT (Figure 2a–c) provides granular evidence of where each modality contributes.

- **Honest reporting of limitations strengthens the paper.** The GO prediction result (F_max 0.57 vs. ESM-2's 0.62) is clearly presented and correctly interpreted as indicating that structure encoders add limited value for homology-driven tasks. The storage trade-off (75 GB for 5,800 proteins) is explicitly noted. The paper also acknowledges the possibility that alternative pretraining objectives (masked voxel prediction, rotation prediction) could yield even better representations.

- **Ablation studies (Figure 2e) justify key design choices.** The 6.4% drop from reducing inference ensemble from 5 to 1 view confirms multi-view averaging is critical. The comparison of contrastive vs. Rosetta pretraining (+1.0%) and the 1.0Å vs. 1.5Å resolution test (+1.1%) provide quantitative justification for the chosen architecture.

## Weaknesses

### Fatal
None.

### Major
- **SOTA comparison lacks controlled re-baselines.** The comparisons to SPOT, ProSmith-ESP, and Fusion_ESP in Section 3.3 do not state whether these baselines were re-run on identical train/test splits or taken verbatim from original papers. There is also a minor numeric discrepancy (text says SPOT achieves 92.3% accuracy, Table 1 lists 92.4%). Without controlled re-evaluation, the reported margins (e.g., 93.2% vs. 92.3%) could reflect dataset partitioning differences rather than model improvements. The paper should either report controlled numbers or clearly state the comparisons are to published results and note the potential confound.

### Minor
- **Ablation numbers are inconsistent between text and Figure 2e table.** The text (Section 4.2) reports: single-view drop of 6.4% (figure says ~-5.5%), no augmentation impact of -0.1% (figure says ~0.4%), contrastive vs. Rosetta gap of 1.0% (figure says ~1.2%), and resolution change of 1.1% (figure says ~0.8%). These need reconciliation.

- **Rotation augmentation is limited to discrete 90° rotations** (the 24-element cubic group), not continuous SO(3). The paper describes this transparently in Section 2.4 but uses phrases like "rotation-robust representations" (abstract) and "aimed to achieve rotation-invariant predictions" (intro) that could oversell the approach. The model relies on inference-time multi-view averaging (5 random views) rather than learned continuous invariance. This is not a fatal flaw — the approach works empirically — but the language should be calibrated to match the discrete augmentation scheme used.

- **ESM-2 fine-tuning protocol is underspecified.** Section 3.1 says "all models were fine-tuned under identical conditions" and describes using the same prediction head and fixed MolFormer embeddings. However, it does not explicitly state whether ESM-2 was fine-tuned end-to-end or used as a frozen feature extractor. Given that ProteinVista clearly states "the entire network is then fine-tuned end-to-end" (Section 2.3), the corresponding statement for ESM-2 should be equally explicit.

- **Contrastive alignment to ESM-2 creates a caveat for the complementarity claim.** The structure encoder is explicitly trained to align its embeddings with a sequence model's embeddings via InfoNCE loss. The paper's own ablation shows that a purely structure-based pretraining objective (Rosetta scores) gives nearly comparable results (only 1.0% behind), and the strong downstream performance suggests some structure-specific information survives the projection. However, the framing of "complementary information" should more directly acknowledge that the pretraining objective partially conflates sequence and structure signals. The paper does discuss this implicitly but could be more upfront.

### Trivial
- Small numeric discrepancy (92.3% vs. 92.4% for SPOT) between text and Table 1.

## Nice-to-Haves

- Testing the model on continuous SO(3) rotations (not just 90° increments) would directly validate whether the rotation-robustness claim holds for arbitrary orientations and could potentially simplify inference by removing the need for multi-view averaging.
- Adding a purely geometric self-supervised pretraining baseline (e.g., masked voxel prediction) would strengthen the complementarity claim by showing what structure-specific signal survives without alignment to a sequence model.
- Reporting effect sizes (e.g., median absolute error difference) alongside the extreme p-value would give a clearer picture of practical significance.

## Removed Points

These points are flagged to be removed; treat them with caution.

- **Harsh critic's concern about the p-value being "suspiciously extreme" (p < 10⁻³⁰⁴).** The critic acknowledges this is plausible given BindingDB's ~100K+ data points. With large sample sizes, extreme p-values are expected for systematic differences. Removed — not a genuine weakness.
- **Harsh critic's claim about "conflating augmentation at training with invariance at inference."** The paper's ablation actually clarifies this distinction: disabling augmentations during fine-tuning has negligible impact (-0.1%) while single-view inference hurts (6.4% drop). The paper correctly interprets this as "the network learns a stable representation already during pre-training." Removed — the paper handles this correctly.
- **Strength Finder's generic strengths about "important problem" and "timely contribution."** These are generic statements not specific to this paper's evidence. Removed.
- **Harsh critic's question about test protein structure source (experimental vs. AF2).** The paper consistently states its pipeline uses only predicted structures (intro: "Because the pipeline uses only predicted structures…"). The pLDDT analysis is specifically about AlphaFold2 confidence scores applied to the test set. Removed — this is clearly stated in the paper.
- **Criticism that the contrastive alignment "creates a circular dependency that may limit the structural signal."** This is a theoretical concern that the paper's empirical evidence largely addresses: the ablation shows Rosetta-only pretraining (purely structural, no sequence alignment) achieves nearly the same results, and the strong downstream performance of ProteinVista demonstrates that useful structure-specific representations survive. Demoted from a major concern to the minor weakness listed above.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. Reconcile the numeric discrepancies between the ablation descriptions in the text (Section 4.2) and the values in Figure 2e's table.
2. Clarify the SOTA comparison: either add a controlled re-baseline for SPOT/ProSmith-ESP/Fusion_ESP on the same splits, or state explicitly that numbers are from published results and add a caveat about potential confounds from differing evaluation protocols.
3. Explicitly state whether ESM-2 was fine-tuned end-to-end or used as a frozen feature extractor in the comparisons.
4. Qualify the rotation-robustness language to match the discrete 90° augmentation scheme actually used, or add an experiment testing continuous rotations.
5. Ensure the open-source repository URL appears in the camera-ready version (presumably in the appendix which the parser stripped).

## Score and Decision

**Bracketing (Round 1):** I queried three bands. Weak anchors (avg < 3.5): papers scoring 3.0–3.4 on molecular GNN/pretraining topics — mostly rejected papers with methodological issues. Middle anchors (3.5–7.5): papers scoring 5.25–6.75 on protein representation learning — generally accepted method papers. Strong anchors (>7.5): papers scoring 8.0 on protein design/docking — very strong, often with theoretical contributions or major empirical advances. This paper clearly sits in the middle band. **Initial bracket: 5.5 – 7.0.**

**Narrowing (Round 2):** I queried within (5.5, 7.5) and examined specific anchors:
- BindNet at 5.67 (protein-ligand binding, accepted): had data leakage concerns and lacked ESM-2 comparison. ProteinVista is stronger — it fairly compares against ESM-2, has cleaner evaluation, and reports limitations honestly.
- ProteinINR at 5.75 (multi-modal, accepted): marginal gains over baselines. ProteinVista shows clearer improvements on key tasks.
- ProteinWorkshop at 6.25 (benchmark, accepted): different contribution type but shows rigorous evaluation. ProteinVista's evaluation is comparably rigorous for a method paper.
- All-atom Geom-GNN at 6.50 (accepted): more theoretical/empirical investigation but less practical demonstration. ProteinVista has cleaner practical wins.

ProteinVista is clearly stronger than the 5.67–5.75 anchors and comparable to the 6.25–6.50 range. The paper's contributions are concrete, the evaluation is fair (ESM-2 under identical conditions), the limitations are honestly reported, and the compute efficiency analysis is a genuine advantage. The weaknesses are real but minor (ablation number inconsistencies, underspecified protocol details) and do not threaten the core claims.

**Final score: 6.5** — a solid, well-executed method paper with clear practical contributions and appropriately scoped claims.

**Decision: Accept.**

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>